InvestorsHub Logo
Followers 61
Posts 3376
Boards Moderated 1
Alias Born 12/26/2012

Re: None

Saturday, 10/12/2013 12:40:03 PM

Saturday, October 12, 2013 12:40:03 PM

Post# of 130513
AMBS will focus on entering into agreements w/ top tier clinical sites to support LymPro clinical studies for AD & other indications

http://ir.stockpr.com/amarantus/all-sec-filings#document-10684-0001144204-13-052051



AD plus OTHER INDICATIONS = $500 Million Dollar Revenue PLUS $Revenue for other Indication(s) ??? How many more How much more revenue potential....